PC
EUCRU

Periscope Capital’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Periscope Capital’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-79,150
Closed -$780K – 1261
2022
Q1 		$780K Buy
+79,150
New +$785K 0.02% 631

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Periscope Capital's EUCRU Position: Q2 2022 in Review

Periscope Capital sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q2 2022, closing a stake of 79,150 shares — an estimated $780K sold.

Periscope Capital first reported a position in EUCRU in Q1 2022 and held it in 1 quarter. The position peaked at $780K in Q1 2022. 17 funds tracked by Wall St. Rank hold EUCRU as of Q2 2022.

  • Periscope Capital reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q2 2022 after selling out during the quarter.
  • Periscope Capital sold 79,150 Eucrates Biomedical Acquisition Corp. Unit shares in Q2 2022, an estimated $780K.
  • Periscope Capital first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q1 2022 and held it in 1 quarter.
  • Periscope Capital's Eucrates Biomedical Acquisition Corp. Unit position peaked at $780K in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q2 2022.

Based on Periscope Capital's 13F filing for Q2 2022, filed 15 Aug 2022.